Hu Tan, Li Deng, Zhao Yang
Department of Cardiovascular Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, PR China.
Mol Immunol. 2009 Dec;47(2-3):298-301. doi: 10.1016/j.molimm.2009.09.020. Epub 2009 Oct 4.
The purpose of the study is to identify the novel approach of hsp110-heparanase vaccine in virtue of the chaperoning properties of hsp110, and to explore the antitumor potential. To test it, the recombinant hsp110 and heparanase proteins form into complex vaccine during heat shock, and the antitumor immunity is observed. We demonstrate that hsp110 and heparanase can form into complex vaccine, and the vaccine can enhance the specific IFN-gamma production and cytotoxic T cell response. Additionally, immunization of the vaccine can also significantly suppress the established tumor growth and prolong the life span of tumor-bearing mice. Thus, the use of the recombinant hsp110 and heparanase proteins to form into complex vaccine represents a novel and promising way for the therapeutical strategy of tumor.
本研究的目的是借助热休克蛋白110（hsp110）的伴侣蛋白特性，确定hsp110-乙酰肝素酶疫苗的新方法，并探索其抗肿瘤潜力。为了进行测试，重组hsp110和乙酰肝素酶蛋白在热休克过程中形成复合疫苗，并观察其抗肿瘤免疫反应。我们证明hsp110和乙酰肝素酶可以形成复合疫苗，并且该疫苗可以增强特异性γ干扰素的产生和细胞毒性T细胞反应。此外，接种该疫苗还可以显著抑制已形成肿瘤的生长，并延长荷瘤小鼠的寿命。因此，利用重组hsp110和乙酰肝素酶蛋白形成复合疫苗代表了一种新型且有前景的肿瘤治疗策略。
